Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Adjust your protocol based on results, always prioritizing sustainable progress over rapid change
The study, presented at the European Congress of Obesity (ECO) and led by researchers at University College London, also found that semaglutide brought about cardiovascular benefits for its participants, regardless of their starting weight or the amount of weight that they had lost
Villumsen M et al
Chronic ethanol ingestion induces oxidative kidney injury through taurine-inhibitable inflammation
Data availability The data underlying this article are available in NAHNES website, at [ Abbreviations ASCVD: Atherosclerotic cardiovascular disease BMI: Body mass index BRC: Biomedical Research Centre CAD: Coronary artery disease CDC: Centers for Disease Control and Prevention CI: Confidence interval CKD: Chronic kidney disease CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration CVD: Cardiovascular disease eGFR: Estimated glomerular filtration rate FDA: Food and Drug Administration GLP-1: Glucagon-like peptide-1 GLP-1 RA: Glucagon-like peptide-1 receptor agonist HbA1c: Glycated haemoglobin HR: Hazard ratio IQR: Interquartile range KDIGO: Kidney disease: improving global outcomes MACE: Major adverse cardiovascular events MEC: Mobile Examination Center MI: Myocardial infarction NCHS: National Center for Health Statistics NHANES: National Health and Nutrition Examination Survey NIHR: National Institute for Health and Care Research NNT: Number needed to treat PAD: Peripheral artery disease SOUL: Semaglutide Cardiovascular Outcomes Trial U.S.: United States UK: United Kingdom References Zhou B, Rayner AW, Gregg EW, Sheffer KE, Carrillo-Larco RM, Bennett JE, et al
In the GLP-1 group, alcohol use disorder was found in 1.4% and cholelithiasis was found in 2.1%
